“The medicine will be available from the following week. It will be supplied orally in Mexico at no cost exclusively in public institutions, both federal and state health, according to the prioritization of groups at high risk of complications, progressively, according to the availability and deliveries of the producing laboratory, as well as progress in distribution to care units predefined by each institution”.
The Pfizer drug was approved by the Federal Commission for the Protection against Sanitary Risks (Cofepris) last January 2022.
While in April of the same year, the World Health Organization (WHO) declared that the combination of nirmatrelvir and ritonavir, whose trade name is Paxlovid, prevents SARS-CoV-2 from replicating, so it is recommended for people with mild or moderate symptoms of COVID-19 and with a high risk of complications.
According to the SSa, from July 25 to 27, health professionals were trained to learn the drug application guidelines, as well as interactions, pharmacovigilance, traceability and periodic use reporting.
